Research Progress of Epidermal Growth Factor Receptor and Molecular-Targeted Therapy in Treatment of Non-Small Cell Lung Cancer
Molecular target therapy has become a new approach in the treatment of advanced non-small cell lung cancer (NSCLC). The sensitivity of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has been found to be associated with gene mutationss in the tyrosine kinase do...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Third Party Medicine International Publishing Group Co. Limited
2014-03-01
|
| Series: | Journal of International Translational Medicine |
| Subjects: | |
| Online Access: | http://www.jitm.hk/EN/abstract/abstract43.shtml |
| Summary: | Molecular target therapy has become a new approach in the treatment of advanced non-small cell lung cancer (NSCLC). The sensitivity of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has been found to be associated with gene mutationss in the tyrosine kinase domain of RGFR. However, not all EGFR gene mutationss are sensitive to EGFR-TKIs. The review was conducted to study the research progress of EGFR mutations and the sensitivity to EGFR-TKIs and the mechanism of resistance of molecular target therapy in NSCLC. |
|---|---|
| ISSN: | 2227-6394 |